Deus ex Makena?
- PMID: 21471852
- DOI: 10.1097/AOG.0b013e31821c6fb1
Deus ex Makena?
Comment in
-
Deus ex Makena?Obstet Gynecol. 2011 Oct;118(4):955; author reply 955-6. doi: 10.1097/AOG.0b013e31822f8774. Obstet Gynecol. 2011. PMID: 21934462 No abstract available.
Comment on
-
Unjustified increase in cost of care resulting from U.S. Food and Drug Administration approval of Makena (17α-hydroxyprogesterone caproate).Obstet Gynecol. 2011 Jun;117(6):1408-1412. doi: 10.1097/AOG.0b013e31821c2d75. Obstet Gynecol. 2011. PMID: 21471853
References
-
- Cohen AW, Copel JA, Macones GA, Menard MK, Riley L, Saade GR. Unjustified increase in cost of care resulting from U.S. Food and Drug Administration approval of Makena (17α-hydroxyprogesterone caproate). Obstet Gynecol 2011;117:1408–12.
-
- Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate [published erratum appears in N Engl J Med 2003;349:1299]. N Engl J Med 2003;348:2379–85.
-
- Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007;357:454–61.
-
- Caritis SN, Rouse DJ, Peaceman AM, Sciscione A, Momirova V, Spong CY. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet Gynecol 2009;113:285–92.
-
- da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419–24.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
